Literature DB >> 18086000

Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.

Mizutomo Azuma1, Michael Shi, Kathleen D Danenberg, Humphrey Gardner, Carl Barrett, Christian J Jacques, Andrew Sherod, Syma Iqbal, Anthony El-Khoueiry, Dongyun Yang, Wu Zhang, Peter V Danenberg, Heinz-Josef Lenz.   

Abstract

OBJECTIVES: In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism (glucose transporter-1 [Glut-1]) and genes involved in angiogenesis (i.e., VEGFA, VEGFR1-3, and neuropilin [NRP]1) are upregulated in metastatic colorectal cancer (mCRC) patients with high serum lactate dehydrogenase (LDH). PATIENTS AND METHODS: 78 formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 36 patients with mCRC. Tumor gene expression was correlated with serum LDH levels from the same group of patients. FFPE tissues were dissected using laser-captured microdissection and analyzed for gene expression using a quantitative real-time RT-PCR method.
RESULTS: Intratumoral gene expression of VEGFA and VEGFR1 showed a statistically significant correlation with serum LDH levels (p = 0.006, r = 0.45 and p = 0.004, r = 0.50, respectively). Intratumoral expression of LDHA gene showed a significant correlation with Glut-1, VEGF, HIF1 alpha, HIF2 alpha and VEGFR1 (p = 0.007, r = 0.44; p < 0.001, r = 0.57; p = 0.013, r = 0.41; p = 0.044, r = 0.34; p = 0.026, r = 0.40). Serum LDH levels also correlated with microvessel density analyzed by immunohistochemical analysis.
CONCLUSION: The results demonstrated a significant correlation between the intratumoral gene expression of LDHA, HIF1 alpha, HIF2 alpha, Glut-1, NRP1, VEGFA and VEGFR1. Patients with high serum LDH have increased intratumoral gene expression of VEGFA and VEGFR1. The results also support the hypothesis that serum LDH levels may serve as a surrogate marker for activation of the HIF-related genes in the tumor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086000     DOI: 10.2217/14622416.8.12.1705

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  22 in total

1.  Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.

Authors:  Richard W Joseph; Ryan J Sullivan; Robyn Harrell; Katherine Stemke-Hale; David Panka; George Manoukian; Andrew Percy; Roland L Bassett; Chaan S Ng; Laszlo Radvanyi; Patrick Hwu; Michael B Atkins; Michael A Davies
Journal:  J Immunother       Date:  2012-01       Impact factor: 4.456

2.  A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth.

Authors:  John C Schell; Kristofor A Olson; Lei Jiang; Amy J Hawkins; Jonathan G Van Vranken; Jianxin Xie; Robert A Egnatchik; Espen G Earl; Ralph J DeBerardinis; Jared Rutter
Journal:  Mol Cell       Date:  2014-10-21       Impact factor: 17.970

3.  Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation.

Authors:  G Larry Maxwell; Brian L Hood; Roger Day; Uma Chandran; David Kirchner; V S Kumar Kolli; Nicolas W Bateman; Jay Allard; Caela Miller; Mai Sun; Melanie S Flint; Chris Zahn; Julie Oliver; Subhadra Banerjee; Tracy Litzi; Anil Parwani; Glenn Sandburg; Scott Rose; Michael J Becich; Andrew Berchuck; Elise Kohn; John I Risinger; Thomas P Conrads
Journal:  Gynecol Oncol       Date:  2011-04-01       Impact factor: 5.482

4.  Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.

Authors:  Xabier Garcia-Albeniz; Carles Pericay; Virginia Alonso-Espinaco; Vicente Alonso; Pilar Escudero; Carlos Fernández-Martos; Rosa Gallego; Pere Gascón; Sergi Castellví-Bel; Joan Maurel
Journal:  Tumour Biol       Date:  2010-11-23

Review 5.  Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.

Authors:  Fausto Petrelli; Andrea Coinu; Mary Cabiddu; Karen Borgonovo; Veronica Lonati; Mara Ghilardi; Sandro Barni
Journal:  Med Oncol       Date:  2015-01-09       Impact factor: 3.064

6.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

7.  Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients.

Authors:  Wanjing Feng; Yue Wang; Xiaodong Zhu
Journal:  Ann Transl Med       Date:  2019-04

8.  Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Efthimios Sivridis; Kevin C Gatter; Tanja Trarbach; Gunnar Folprecht; Michael M Shi; David Lebwohl; Tarja Jalava; Dirk Laurent; Gerold Meinhardt; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

9.  Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.

Authors:  M Scartozzi; R Giampieri; E Maccaroni; M Del Prete; L Faloppi; M Bianconi; E Galizia; C Loretelli; L Belvederesi; A Bittoni; S Cascinu
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

10.  Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.

Authors:  Qiong Yang; Chenxi Yin; Fangxin Liao; Yuanyuan Huang; Wenzhuo He; Chang Jiang; Guifang Guo; Bei Zhang; Liangping Xia
Journal:  Onco Targets Ther       Date:  2015-09-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.